| Acronym | Meaning |
| ABG | Arterial Blood Gas |
| AIHA | Autoimmune Hemolytic Anemia |
| Alb | Albumin |
| ALC | Absolute Lymphocyte Count |
| ANC | Absolute Neutrophil Count |
| BCL-2 | B-cell lymphoma 2 (a gene regulating cell death- inhibitors may help control CLL) |
| BCR | B-cell Receptor |
| BMBx | Bone Marrow Biopsy |
| BMT | Bone Marrow Transplant |
| BR | Bendamustine and Rituximab |
| BTK | Bruton’s Tyrosine Kinase (inhibitors help may control CLL) |
| BUN | Blood Urea Nitrogen |
| Ca | Calcium |
| CAM | Complementary and Alternative Medicine |
| CAR-T | Chimeric Antigen Receptor T-cell |
| CBC | Complete Blood Count |
| CD | Cluster of Differentiation (targets that allow immunophenotyping and diagnosis) |
| Cl | Chlorine |
| CLL | Chronic Lymphocytic Leukemia |
| CO2 | Carbon Dioxide |
| Cr | Creatinine |
| CR | Complete Response |
| FCR | Fludarabine, Cyclophosphamide, Rituximab |
| FISH | Fluorescence In Situ Hybridization |
| GVHD | Graft Versus Host Disease |
| HDMP | High dose methyl-prednisolone |
| HGB | Hemoglobin level |
| HCT | Hematocrit |
| HLA | Human Leukocyte Antigen |
| HSCT | Hematopoietic Stem Cell Transplant |
| ITP | Idiopathic (or Immune) Thrombocytopenic Purpura |
| K | Potassium |
| LDT | Lymphocyte Doubling Time |
| LDH | Lactate Dehydrogenase |
| MCV | Mean Corpuscular Volume |
| MCH | Mean Corpuscular Hemoglobin |
| MCHC | Mean Corpuscular Hemoglobin Concentration |
| MDS | Myelodysplastic Syndromes |
| MPV | Mean Platelet Volume |
| MRD | Minimal Residual Disease |
| Na | Sodium |
| O2 | Oxygen |
| OS | Overall Survival |
| PCR | Polymerase Chain Reaction |
| PFS | Progression Free Survival |
| PI3K | Phosphoinositide 3-kinase (inhibitors help control CLL) |
| PLT | Platelets |
| PR | Partial Response |
| R | Rituximab |
| RBC | Red Blood Cell |
| RDW | Red cell Distribution Width |
| SCT | Stem Cell Transplant |
| SGPT | Serum Glutamic Pyruvic Transaminase |
| SLL | Small Lymphocytic Lymphoma |
| TBI | Total Body Irradiation |
| TKI | Tyrosine Kinase Inhibitors |
| TLS | Tumor Lysis Syndrome |
| TTT | Time to Treat |
| URI | Upper Respiratory Infection |
| WBC | White Blood Cells |
| W&W | Watch and Wait |
-
Pingback: ESH 2014: Prof. Michael Hallek Discusses Clinical Trial Goals in CLL - CLL Society
-
Pingback: Clinical Trial Goals in CLL
-
Pingback: ASH 2014: Dr. Jan Burger on Ibrutinib Resistance in CLL (chronic lymphocytic leukemia): Next Steps: Transplants and Trials (Part 1) - CLL Society
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL
-
Pingback: New Targeted Therapies for Chronic Lymphocytic Leukemia
-
Pingback: Complex Karyotype in CLL Predicts Inferior Outcomes with Ibrutinib Therapy - CLL Society
-
Pingback: Symptoms of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: Diagnosis of Chronic Lymphocytic Leukemia - CLL Society
-
Pingback: ASH 2015: Dr. Stephan Stilgenbauer on Dramatic Responses to Venetoclax in relapsed/ refractory (R/R) 17p deleted CLL - CLL Society
Leave Comment